Aligos Therapeutics, Inc.
ALGS
$5.67
-$0.09-1.56%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 881.55% | 1,574.56% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 881.55% | 1,574.56% | |||
| Cost of Revenue | 3,511.11% | -96.09% | |||
| Gross Profit | 72.27% | 112.83% | |||
| SG&A Expenses | -12.31% | 29.57% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -0.31% | 35.37% | |||
| Operating Income | 92.98% | -23.45% | |||
| Income Before Tax | 105.75% | -14.47% | |||
| Income Tax Expenses | 786.75% | 956.67% | |||
| Earnings from Continuing Operations | 93.47% | -15.89% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 93.47% | -15.89% | |||
| EBIT | 92.98% | -23.45% | |||
| EBITDA | 93.85% | -23.31% | |||
| EPS Basic | 93.49% | -15.68% | |||
| Normalized Basic EPS | 105.74% | -14.26% | |||
| EPS Diluted | 93.49% | -15.53% | |||
| Normalized Diluted EPS | 105.74% | -14.26% | |||
| Average Basic Shares Outstanding | 0.27% | 0.19% | |||
| Average Diluted Shares Outstanding | 0.27% | 0.19% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||